PSDV pSivida Corp.

2.22
+0.09  (4%)
Previous Close 2.13
Open 2.14
Price To book 6.07
Market Cap 87.17M
Shares 39,268,000
Volume 548,921
Short Ratio 1.90
Av. Daily Volume 378,198

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 2015. Second Phase 3 trial data due June 2017 with NDA to be filed 4Q 2017.
Medidur
Posterior uveitis
CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. ETFs with exposure to pSivida Corp. : May 22, 2017
  2. pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017
  3. Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
  4. Today's Research Reports on Kratos Defense & Security Solutions and pSivida Post Earnings
  5. Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT
  6. PSivida reports 3Q loss
  7. pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
  8. Investor Network: pSivida Corp. to Host Earnings Call
  9. pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
  10. ETFs with exposure to pSivida Corp. : April 11, 2017
  11. ETFs with exposure to pSivida Corp. : March 30, 2017
  12. pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017
  13. Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  14. Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT
  15. PSivida posts 2Q loss
  16. pSivida Corp. (PSDV): Here’s How It Stacks Up Versus Its Peers
  17. ETFs with exposure to pSivida Corp. : December 13, 2016